Patients’ baseline characteristics.
| Characteristic | Nonresponse (A) n = 49 | Loss of Response (B) n = 75 | Adverse Events (C) n = 73 | p |
|---|---|---|---|---|
| Female (%) | 29 (59.2) | 46 (75.3) | 55 (75.3) | 0.101 |
| Age, yrs, mean (SD) | 54 (12) | 55 (12) | 55 (12) | 0.970 |
| Disease duration, yrs, median (range) | 6 (0.7–37) | 7 (1–55) | 10 (0.5–46) | 0.074 |
| RF-positive (%) | 41 (83.7) | 56 (74.7) | 54 (74) | 0.405 |
| No. previous DMARD, median (range)* | 3 (2–10) | 3 (1–8) | 4 (1–9) | 0.463 |
| DAS28 at baseline 2nd anti-TNF agent, mean (SD) | 5.8 (1.1) | 4.9 (1.1) | 4.8 (1.3) | < 0.0001 |
| 1st anti-TNF agent used | ||||
| Infliximab (%) | 18 (36.7) | 29 (38.7) | 44 (60.3) | 0.010 |
| Etanercept (%) | 16 (32.7) | 27 (36.0) | 12 (16.4) | 0.021 |
| Adalimumab (%) | 15 (30.6) | 19 (25.3) | 17 (23.3) | 0.657 |
| 2nd anti-TNF agent used | ||||
| Infliximab (%) | 2 (4.1) | 2 (2.7) | 1 (1.4) | 0.644 |
| Etanercept (%) | 30 (61.2) | 34 (45.3) | 45 (61.6) | 0.086 |
| Adalimumab (%) | 17 (34.7) | 39 (52) | 27 (37) | 0.086 |
| Switch of therapy | ||||
| Antibody to receptor blocker (%) | 30 (61.2) | 34 (45.3) | 45 (61.6) | 0.086 |
| Receptor blocker to antibody (%) | 16 (32.7) | 27 (36) | 12 (16.4) | 0.021 |
| Antibody to antibody (%) | 3 (6.1) | 14 (18.7) | 16 (22) | 0.062 |
| Concurrent medication 2nd anti-TNF agent used** | ||||
| MTX (%) | 23 (46.9) | 41 (54.7) | 28 (38.4) | 0.138 |
| Other DMARD (%) | 7 (14.3) | 21 (28.0) | 19 (26.0) | 0.186 |
| Corticosteroids (%) | 28 (57.1) | 27 (36) | 16 (21.9) | < 0.0001 |